Q: What is your responsibility when selecting and/or working with these early stage companies? A: NCI SBIR Program Directors do not play a role in reviewing the SBIR/STTR applications. That process is done at the NIH Peer Review panel....
Q: There are various new, emerging therapeutics that bring us closer towards a cure for life-threatening disorders such as cancer, HIV, or Huntington’s disease. Prominent examples include the popular gene editing tool CRISPR or new and improved cell and gene therapies. By when can we...
Q: Your current focus is on creating a large-scale biomedical data analytics platform, a “data lake” that aggregates and provides access to various types of data, including EMR, omics, clinical data, ECG, imaging, population health, and wearable devices data and is linked for analytical access...
Q: Helix is involved in a number of major population initiatives that have recently been launched. can you tell us more about these initiatives - what are their goals and what is Helix’s role? A: We are proud to work with health systems across the US...
Q: The prevalence of metabolic syndrome in patients with schizophrenia is much higher compared to the general population. What is the role of folate pharmacogenomics on inflammatory and metabolic complications from atypical antipsychotic use in schizophrenia? A: The folate hypothesis of schizophrenia is an emerging field...
Q: Cancer Genomic Profiling is being used more routinely as standard of care in many cancer types. To date, it has been used to determine what therapies are most likely to work on that tumor, prognosis for that patient, and to uncover clinical trial...
Q: Interpreting data at the point of care has its challenges, especially when it comes to integrating the various types of data for combined analysis and clinical applications (e.g. clinical, imaging, and genomics data). What are some of the challenges the industry is facing and...
Q: Approximately 10% of pediatric patients with acute lymphoblastic leukemia (ALL) are not cured by current therapy because of the development of drug resistance. What are some of the known mechanisms of drug resistance, and what are the emerging therapeutics to mitigate resistance? A: The...
Q: What is it to be overwhelmed by the need to act? A: It only takes one experience of a loved one's diagnosis of advanced cancer to be jarred, because quite frankly, navigating a cancer diagnosis is a nightmare. ...
Clinical genomics is often considered to be risky for commercial labs to spin up because of concerns around profitability. Two commonly invoked reasons for this are under resourced billing and authorization services at medical centers and poor reimbursement of the tests. ...
